{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "I",
          "alt": "T",
          "position": "2020"
        },
        "variant_string_id": "LRRK2 I2020T"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in LRRK2 cause Parkinson's disease (PD), and the variants I2020T/G2019S alter kinase activity via ATP affinity changes.",
          "step_result": "Yes"
        },
        {
          "step_name": "Step 2: Evaluate assay type",
          "extracted_paper_info": "Binding/kinase assays assess ATP affinity and inhibitor resistance, directly linking to PD pathogenesis.",
          "step_result": "Yes"
        },
        {
          "step_name": "Step 3a: Basic Controls",
          "extracted_paper_info": "Wild-type LRRK2 is used as a control, but no explicit null mutant or variant controls are mentioned.",
          "step_result": "No"
        },
        {
          "step_name": "Step 3b: Validated Assays",
          "extracted_paper_info": "Prior studies ([3][4][5][6][7][8][9]) validate kinase assays for LRRK2 variants, confirming methodological reliability.",
          "step_result": "Yes"
        },
        {
          "step_name": "Step 4a: Statistical Analyses",
          "extracted_paper_info": "Quantitative comparisons (e.g., 6-fold higher ATP affinity, 10-fold inhibitor resistance) with statistical significance implied.",
          "step_result": "Yes"
        },
        {
          "step_name": "Step 4c: Correlate OddsPath",
          "extracted_paper_info": "I2020T shows 10-fold inhibitor resistance (strong effect), G2019S shows 1.6-fold increased sensitivity (moderate effect).",
          "step_result": "PS3_very_strong"
        }
      ],
      "final_strength": "PS3_very_strong"
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "G",
          "alt": "S",
          "position": "2019"
        },
        "variant_string_id": "LRRK2 G2019S"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in LRRK2 cause PD, and the variant G2019S alters kinase activity via ATP affinity changes.",
          "step_result": "Yes"
        },
        {
          "step_name": "Step 2: Evaluate assay type",
          "extracted_paper_info": "Binding/kinase assays assess ATP affinity and inhibitor resistance, directly linking to PD pathogenesis.",
          "step_result": "Yes"
        },
        {
          "step_name": "Step 3a: Basic Controls",
          "extracted_paper_info": "Wild-type LRRK2 is used as a control, but no explicit null mutant or variant controls are mentioned.",
          "step_result": "No"
        },
        {
          "step_name": "Step 3b: Validated Assays",
          "extracted_paper_info": "Prior studies ([3][4][5][6][7][8][9]) validate kinase assays for LRRK2 variants, confirming methodological reliability.",
          "step_result": "Yes"
        },
        {
          "step_name": "Step 4a: Statistical Analyses",
          "extracted_paper_info": "Quantitative comparisons (e.g., 2-fold lower ATP affinity, 1.6-fold inhibitor sensitivity) with statistical significance implied.",
          "step_result": "Yes"
        },
        {
          "step_name": "Step 4c: Correlate OddsPath",
          "extracted_paper_info": "G2019S shows 1.6-fold increased inhibitor sensitivity (moderate effect), consistent with pathogenic functional evidence.",
          "step_result": "PS3_moderate"
        }
      ],
      "final_strength": "PS3_moderate"
    }
  ]
}